Please assess the completion status of the following clinical trial:

Trial Title: Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be ≥ 18 years of age~* Patients with histologically diagnosed relapsed high grade serous ovarian cancer (including primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer. Patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease \>6 months (\>/=183 days) after completion of their last platinum therapy.~* Documented germline mutation in Breast Cancer susceptibility genes: BRCA1 and/or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)~* At least one lesion that can be accurately assessed at baseline by CT/MRI and is suitable for repeated assessment.~* Patients must have received at least 2 prior platinum based lines of chemotherapy - Patients must be partially platinum sensitive or platinum sensitive~* Patients must be suitable to start treatment with single agent chemotherapy based on physician's choice~* Patients must have normal organ and bone marrow function measured within 28 days of randomisation,~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Patients must have a life expectancy ≥ 16 weeks~* Formalin fixed, paraffin embedded tumour sample from the primary or recurrent cancer must be available for central testing.~Exclusion Criteria:~* BRCA 1 and/or BRCA2 mutations that are considered to be non detrimental~* Exposure to any investigational product within 30 days or 5 half lives (whichever is longer) prior to randomisation~* Any previous treatment with a Polyadenosine 5'diphosphoribose polymerisation (PARP) inhibitor, including olaparib.~* Patients who have platinum resistant or refractory disease~* Patients receiving any systemic chemotherapy within 3 weeks prior to first dose of study treatment~* Previous single agent exposure to the selected chemotherapy regimen for randomisation. - Prior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1/OLAPARIB (Type: EXPERIMENTAL): olaparib 300mg oral tablets; twice daily
- 2/CHEMOTHERAPY (Type: ACTIVE_COMPARATOR): Physician's choice single agent chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).